If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced the powerful effects of this weight loss ...

An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Dr. Sue Mitchell is an experienced gastroenterologist with a background in functional medicine, internal medicine and ...

A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

World-Renowned Bariatric Surgeon Dr. Amit Taggar Tampa's newest weight loss center offers advanced robotic bariatric surgery, free ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and ...

especially those who’ve felt stuck in their weight loss journey or haven’t seen success with other methods. These higher doses of semaglutide offer a proven, evidence-based solution to help ...